Enliven Therapeutics reported a third-quarter net loss of $27.7 million, compared to a $20.1 million loss in the prior-year period. Research and development expenses rose to $28.0 million from $18.2 million, while general and administrative costs increased to $8.0 million from $6.9 million. The company highlighted that it reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial for relcobatinib in chronic myeloid leukemia patients and remains on track to initiate the study before year-end 2026. Enliven also announced a strong balance sheet with $884 million in cash, cash equivalents, and marketable securities, providing a runway into 2030. The company appointed Kristine Ball to its Board of Directors. Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics.
